Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Specimen Handling 629pembrolizumab 559Magnetic Resonance Spectroscopy 539Carboplatin 423Cyclophosphamide 371Cisplatin 371Biopsy 357Paclitaxel 304Nivolumab 301Gemcitabine 299Radiotherapy 270Bevacizumab 238Dexamethasone 207fludarabine 205Docetaxel 189durvalumab 178atezolizumab 176Oxaliplatin 172Fluorouracil 167venetoclax 164Rituximab 164Pemetrexed 162Radiation 159Doxorubicin 159Capecitabine 158Radiosurgery 147Etoposide 137Ipilimumab 134Leucovorin 133Lenalidomide 130

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
voruciclib × 90 days × Clear all
NCT03547115 2026-03-17

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

MEI Pharma, Inc.

Phase 1 Terminated
84 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡